EIKEN軍團(tuán)菌快速檢測卡

廣州健侖生物科技有限公司

主要用途：用于檢測尿樣中嗜肺軍團(tuán)菌血清型1抗原，以支持軍團(tuán)菌感染的診斷。

產(chǎn)品規(guī)格：20T/盒

存儲條件：2-30℃

EIKEN軍團(tuán)菌快速檢測卡

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

【產(chǎn)品介紹】

EIKEN

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化】

Shaw說：“好消息是，這一發(fā)現(xiàn)可預(yù)測，缺失任一基因的患者，應(yīng)該會對靶定粘著斑酶的新療法發(fā)生反應(yīng)，當(dāng)前這種療法癥處于早期臨床試驗(yàn)的檢測當(dāng)中。”
Goodwin補(bǔ)充說：“通過識別某些腫瘤中DIXDC1和LKB1之間這種意想不到的關(guān)聯(lián)，我們已經(jīng)擴(kuò)大了潛在的患者群體，他們可能是這些療法的優(yōu)秀候選人。”
老年群體抗原抗體益增多癡呆患者的現(xiàn)象對現(xiàn)行的醫(yī)療體系是個巨大的考驗(yàn)。阿爾茨海默病(AD)、帕金森綜合癥(PD)，以及額顳區(qū)癡呆(Frontotemporal dementia)患者的腦部病灶都存有異常的大量不溶蛋白質(zhì)，會導(dǎo)致神經(jīng)元的大量丟失。為了減少這些不溶蛋白質(zhì)造成的長期損傷，凋亡的細(xì)胞和聚集的蛋白質(zhì)必須被有效地降解或清除，這正是被稱為小神經(jīng)膠質(zhì)細(xì)胞(Microglia)這種特殊的吞噬細(xì)胞的作用所在。小神經(jīng)膠質(zhì)細(xì)胞僅存于中央神經(jīng)系統(tǒng)，屬于先天性免疫體系的一部分，它就像大腦的衛(wèi)生檢查員，確保垃圾被及時清除，以免這些垃圾威脅到周邊正常細(xì)胞。
該研究發(fā)現(xiàn)，TREM2 基因能調(diào)節(jié)小神經(jīng)膠質(zhì)細(xì)胞的吞噬效率。正常情況下，TREM2嵌入小神經(jīng)膠質(zhì)細(xì)胞的外膜，膜以外的功能域能識別死亡細(xì)胞留下的碎片。然而，TREM2基因的特定突變會干擾蛋白質(zhì)合成過程中蛋白鏈的正常折疊，使之在運(yùn)送到小神經(jīng)膠質(zhì)細(xì)胞外膜之前就被降解了，導(dǎo)致小神經(jīng)膠質(zhì)細(xì)胞處理細(xì)胞碎片的效率降低，繼而那些有毒的不溶蛋白質(zhì)以及凋亡的細(xì)胞在大腦聚集，并觸發(fā)炎癥反應(yīng)，導(dǎo)致神經(jīng)元受損。
研究人員表示，這項(xiàng)新發(fā)現(xiàn)明確了多種不同腦部疾病的共同機(jī)理，并為延緩那些已經(jīng)表征癡呆癥狀的患者的治療指明了道路。
老年群體抗原抗體益增多癡呆患者的現(xiàn)象對現(xiàn)行的醫(yī)療體系是個巨大的考驗(yàn)。阿爾茨海默病(AD)、帕金森綜合癥(PD)，以及額顳區(qū)癡呆(Frontotemporal dementia)患者的腦部病灶都存有異常的大量不溶蛋白質(zhì)，會導(dǎo)致神經(jīng)元的大量丟失。為了減少這些不溶蛋白質(zhì)造成的長期損傷，凋亡的細(xì)胞和聚集的蛋白質(zhì)必須被有效地降解或清除，這正是被稱為小神經(jīng)膠質(zhì)細(xì)胞(Microglia)這種特殊的吞噬細(xì)胞的作用所在。小神經(jīng)膠質(zhì)細(xì)胞僅存于中央神經(jīng)系統(tǒng)，屬于先天性免疫體系的一部分，它就像大腦的衛(wèi)生檢查員，確保垃圾被及時清除，以免這些垃圾威脅到周邊正常細(xì)胞。
該研究發(fā)現(xiàn)，TREM2 基因能調(diào)節(jié)小神經(jīng)膠質(zhì)細(xì)胞的吞噬效率。正常情況下，TREM2嵌入小神經(jīng)膠質(zhì)細(xì)胞的外膜，膜以外的功能域能識別死亡細(xì)胞留下的碎片。然而，TREM2基因的特定突變會干擾蛋白質(zhì)合成過程中蛋白鏈的正常折疊，使之在運(yùn)送到小神經(jīng)膠質(zhì)細(xì)胞外膜之前就被降解了，導(dǎo)致小神經(jīng)膠質(zhì)細(xì)胞處理細(xì)胞碎片的效率降低，繼而那些有毒的不溶蛋白質(zhì)以及凋亡的細(xì)胞在大腦聚集，并觸發(fā)炎癥反應(yīng)，導(dǎo)致神經(jīng)元受損。

The good news is, "The good news is that the finding predicts that patients who lack either gene should respond to new therapies targeting the focal adhesion enzyme, which is currently being tested in early clinical trials."
Goodwin added: "By identifying this unexpected association between DIXDC1 and LKB1 in some tumors, we have expanded the potential patient population, who may be excellent candidates for these therapies."
Antibiotics in the elderly population increases the number of patients with dementia on the current medical system is a huge test. Alzheimer's disease (AD), Parkinson's disease (PD), and brain lesions in patients with frontotemporal dementia have abnormally large amounts of insoluble proteins that result in substantial neuronal loss. In order to reduce the long-term damage caused by these insoluble proteins, apoptotic cells and aggregated proteins must be effectively degraded or cleared, which is what is known as the special phagocyte called microglia. Microglia, which reside only in the central nervous system and are part of the innate immune system, acts like a brain health inspector to ensure that rubbish is removed in time to prevent the rubbish from threatening the surrounding normal cells.
The study found that, TREM2 gene can regulate the phagocytic efficiency of microglia. Under normal circumstances, TREM2 embedded in the outer membrane of microglial cells, the membrane outside the domain can identify the debris left by dead cells. However, certain mutations in the TREM2 gene interfere with the normal folding of protein chains during protein synthesis, degrading them before they are delivered to the outer microglia, resulting in a reduction in the efficiency of microglial cells handling cell debris, Then those toxic insoluble proteins and apoptotic cells accumulate in the brain and trigger an inflammatory response, leading to neuronal damage.
The researchers said the new findings pinpoint common causes of many different brain diseases and point the way to delaying the treatment of those who already have symptoms of dementia.
Antibiotics in the elderly population increases the number of patients with dementia on the current medical system is a huge test. Alzheimer's disease (AD), Parkinson's disease (PD), and brain lesions in patients with frontotemporal dementia have abnormally large amounts of insoluble proteins that result in substantial neuronal loss. In order to reduce the long-term damage caused by these insoluble proteins, apoptotic cells and aggregated proteins must be effectively degraded or cleared, which is what is known as the special phagocyte called microglia. Microglia, which reside only in the central nervous system and are part of the innate immune system, acts like a brain health inspector to ensure that rubbish is removed in time to prevent the rubbish from threatening the surrounding normal cells.
The study found that, TREM2 gene can regulate the phagocytic efficiency of microglia. Under normal circumstances, TREM2 embedded in the outer membrane of microglial cells, the membrane outside the domain can identify the debris left by dead cells. However, certain mutations in the TREM2 gene interfere with the normal folding of protein chains during protein synthesis, degrading them before they are delivered to the outer microglia, resulting in a reduction in the efficiency of microglial cells handling cell debris, Then those toxic insoluble proteins and apoptotic cells accumulate in the brain and trigger an inflammatory response, leading to neuronal damage.